Francesca N. Azar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francesca N. Azar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Audrey M. Putelo
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia
27 shared publications - Melanie R. Rutkowski
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia
27 shared publications - Mitchell T. McGinty
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia
27 shared publications - Sree H. Kolli
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia
27 shared publications - Tzu-Yu Feng
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia
27 shared publications - Anwaruddin Mohammad
Department of Public Health Sciences, University of Virginia, Charlottesville, VA 22904, USA
22 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure 1 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S1. Temporal analysis of TLR5 expression in myeloid and dendritic cell populations within tumor-draining lymph nodes, systemically within the spleen, and within the tumor microenvironment of TLR5 reporter mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure 1 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S1. Temporal analysis of TLR5 expression in myeloid and dendritic cell populations within tumor-draining lymph nodes, systemically within the spleen, and within the tumor microenvironment of TLR5 reporter mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Supplementary Table S3 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Supplementary Table S3 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Supplementary Table S2 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Supplementary Table S2 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure 5 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S5. CITE-seq from FLT3L expanded bone marrow with or without chronic flagellin stimulation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure 5 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S5. CITE-seq from FLT3L expanded bone marrow with or without chronic flagellin stimulation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure 6 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S6. Assessment of temporal changes in CD4 and CD8 T cells from the ovarian tumor microenvironment and tumor-draining lymph node in wild type and TLR5 KO ovarian tumor bearing mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure 6 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S6. Assessment of temporal changes in CD4 and CD8 T cells from the ovarian tumor microenvironment and tumor-draining lymph node in wild type and TLR5 KO ovarian tumor bearing mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure 3 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S3. Comparative analysis of WT and TLR5 KO DC subsets within the same ovarian tumor microenvironment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure 3 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S3. Comparative analysis of WT and TLR5 KO DC subsets within the same ovarian tumor microenvironment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure 4 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S4. Phenotypic assessment of FLT3L cultured bone marrow-derived dendritic cells with acute or chronic exposure to bacterial flagellin
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure 4 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S4. Phenotypic assessment of FLT3L cultured bone marrow-derived dendritic cells with acute or chronic exposure to bacterial flagellin
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure 7 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S7. Immune phenotyping of TLR5fl/fl x CD11c Cre mice bearing ovarian tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure 7 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S7. Immune phenotyping of TLR5fl/fl x CD11c Cre mice bearing ovarian tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure 2 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S2. Dendritic cell subsets examined within the tumor microenvironment and tumordraining lymph nodes in tumor-bearing wild type and TLR5 KO mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure 2 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
Figure S2. Dendritic cell subsets examined within the tumor microenvironment and tumordraining lymph nodes in tumor-bearing wild type and TLR5 KO mice.